.delta.-(S-methylisothioureido)-L-norvaline therapeutic for cerebrovascular diseases having nitric oxide synthase inhibiting factor
Compound represented by the formula (I): ##STR1## or pharmaceutically acceptable salts thereof, as well as therapeutics for cerebrovascular diseases containing such compounds or salts as an active ingredient. The compounds are capable of selective inhibition of nitric oxide synthase in neurons and, hence, are useful as the active ingredient of therapeutics for cerebrovascular diseases.
Latest Chugai Seiyaku Kabushiki Kaisha Patents:
- ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO PLURALITY OF ANTIGEN MOLECULES REPEATEDLY
- ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES
- SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
- COMPOSITION FOR TREATING IL-6-RELATED DISEASES
- METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR
Claims
1. A method of treating a subject having cerebral edema, or of prophylaxis of cerebral edema in a subject diagnosed as being at risk therefor, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition that contains.delta.-(S-methylisothioureido)-L-norvaline, which selectively inhibits neuronal constitutive nitric oxide synthase (N-cNOS) in preference to endothelial constitutive nitric oxide synthase (E-cNOS) as indicated by an IC.sub.50 (E-cNOS) to IC.sub.50 (N-cNOS) ratio of at least 30, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
5364881 | November 15, 1994 | Griffith et al. |
Type: Grant
Filed: Aug 21, 1996
Date of Patent: Feb 9, 1999
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo)
Inventors: Toshihiko Makino (Shizuoka-ken), Toshiaki Nagafuji (Shizuoka-ken)
Primary Examiner: Michael G. Ambrose
Law Firm: Browdy and Neimark
Application Number: 8/696,866
International Classification: A61K 3121;